Even before the draft sequence of the human genome was completed, investors and companies were looking to the 'next big thing' ― proteomics. Huge amounts of time and money were invested in proteomics-related ventures, and a crop of start-up companies emerged. Some firms set up large-scale proteomics factories running around the clock, with the aim of taking an inventory of the entire human proteome. A few years down the line, reality is setting in. How to turn proteomics data into products remains an open question and investors are becoming impatient.
展开▼
